| |
Home »
News » 12/05 »
GlaxoSmithKline's cervical cancer vaccine more effective in younger
girls
GlaxoSmithKline's cervical cancer vaccine more effective in
younger girls
Date published: 19/12/2005
A vaccine
designed to fight a cause of cervical cancer has been found to be effective in
young girls. GlaxoSmithKline (GSK) said that Cervarix produced antibodies twice
as fast in girls aged ten to 14 than in young woman 15 to 25 years old. The
drug is designed to fight the human papilloma virus (HPV), which causes 70 per
cent of cervical cancer cases.
GSK's findings are controversial as the
virus is spread through sexual transmission. The research suggests that the
vaccine will last longer if given to children at an earlier age. It was still
found to be effective enough to fight the virus in 15 to 25 year olds,
however.
eaking to Bloomberg, GSK's Gary Dubin said that early use would
produce the most benefit from the vaccine: "HPV infections are acquired fairly
quickly after becoming sexually active, therefore you need to vaccinate girls
at a fairly young age.
"Now we know we can vaccinate to age ten and the
vaccine appears safe, generates even better responses and suggests protection
achieved in young girls will last a long time."
Rival drugmaker Merck
has already filed an application with the Food and Drug Administration for
rival vaccine Gardasil, which has also been found to be effective amongst the
same age group. "We're pretty close and we hope to announce a filing date
soon," Mr Dubin added.
© Adfero Ltd
Disclaimer
AllAboutMedicalSales excludes any warranty, express or implied, as to
the quality, accuracy, timeliness, completeness or fitness for a particular
purpose of this briefing. AllAboutMedicalSales will not be liable for any
claims, penalties, losses, damages, costs, or expenses arising from the use of
or inability to use this briefing or from any unauthorised access to or
alteration of the Briefing. AllAboutMedicalSales makes no warranty that the
contents of this briefing are compatible with all computer systems and
browsers.
|